Study Finds Correlation Between Pericardial Reconstruction with CorMatrix Cardiovascular ECM(TM) Technology and Reduced Risk of Postoperative Atrial Fibrillation in CABG Patients

ATLANTA--(BUSINESS WIRE)--CorMatrix Cardiovascular, Inc., a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body’s innate ability to repair damaged cardiovascular tissue, announced today that a retrospective study demonstrated that reconstructing the pericardium using ECM™ Technology in patients undergoing primary isolated coronary artery bypass grafting (CABG) contributed to a statistically significant and clinically meaningful reduction in the rate of new onset postoperative atrial fibrillation. This research was published today in the online peer-reviewed journal The Heart Surgery Forum (www.hsforum.com/).